On Monday, Germany-based SAP SE (NYSE:SAP) unveiled a suite of new AI, data, and application innovations designed to accelerate business transformation at its first-ever SAP Connect event. The ...

Recent polls show President Donald Trump's approval rating is around 40% to 45%. Trump's approval ratings in the first year of his terms have been lower than other modern presidents at the same point.

A government shutdown has entered its 10th day (Oct. 10, 2025) after the Senate rejected 2 separate funding bills. President Trump has threatened to cut "Democrat programs" and block back pay for some ...

Donald Trump's presidential job approval rating and the Democratic party's favorability are shifting amid the government shutdown, but how do they compare ahead of the midterms? Here's what the ...

New Mexico’s ‘Free’ Child Care an Attempt to Cover for Past Failures The Virtue of Liberty: A Response to the NatCons Trump Administration Says Drug-Boat Strikes Are Not Really ‘Hostilities,’ as Death ...

Stablecoin payment volumes have grown to $19.4B year-to-date in 2025. OwlTing aims to capture this market by developing payment infrastructure that processes transactions in seconds for fractions of a ...

Novartis (NYSE:NVS) is one of the best growth stocks to buy now. On September 30, Novartis announced the US FDA approval of its drug, Rhapsido (remibrutinib). This oral pill is approved for use in ...

Donald Trump’s approval rating has plummeted, with a majority of Americans opposing the deployment of the National Guard to US cities, according to a new poll. Only 40 percent of people surveyed have ...

Robin has worked as a credit cards, editor and spokesperson for over a decade. Prior to Forbes Advisor, she also covered credit cards and related content for other national web publications including ...

President Donald Trump’s approval rating has rebounded among key demographic groups after hitting record lows last week, according to new polling. New YouGov/Economist polling, conducted between ...

More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...